You are here:

AOP Orphan Contact

AOP Orphan worldwide

Wilhelminenstraße 91/IIf
1160 Vienna, Austria

AOP Orphan is the winner of the MERCUR Innovation Award in the category Life Science for the clinical development project “Ropeginterferon α-2b”

On November 13th AOP Orphan was awarded with the MERCUR prize for Innovation in Life Science by the Chamber of Commerce in Vienna, Austria. We feel very proud to receive this recognition and want to thank all colleagues, partners and the scientific community who have supported and made this project happen over the last years and work every day to bring it even further for the benefit of the patients with the rare disease Polycythemia vera.

MERCUR is the innovation prize of the Vienna Chamber of Commerce, acknowledging Viennese entrepreneurs and their innovative projects.

AOP Orphan award’s submission referred to the clinical phase III study PROUD-PV with patients diagnosed with the rare disease Polycythemia vera. This is the largest randomized study performed so far in this indication. The data have and will be shared at major scientific meetings, like the renowned Annual Meeting of the American Society of Hematology (ASH).